Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease

Merinopoulos, Ioannis, Gunawardena, Tharusha, Corballis, Natasha, Tsampasian, Vasiliki, Vassiliou, Vassilios ORCID: https://orcid.org/0000-0002-4005-7752, Eccleshall, Simon, Ryding, Alisdair and Xydopoulos, George (2023) Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease. Catheterization and Cardiovascular Interventions, 102 (6). pp. 987-996. ISSN 1522-1946

[thumbnail of Merinopoulos_etal_2023_CaCI]
Preview
PDF (Merinopoulos_etal_2023_CaCI) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (972kB) | Preview

Abstract

Aims: We aimed to perform a cost analysis of drug coated balloon (DCB)-only angioplasty versus drug eluting stent (DES), for de novo disease of all vessel sizes and all clinical indications. Background: DCB angioplasty is an emergent technology for the treatment of coronary artery disease. There is lack of data regarding the cost-effectiveness of DCB-only angioplasty for treatment of de novo coronary artery disease as compared with second generation DES. Methods: We compared total costs of patients treated with DCB or DES for first presentation of ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or stable angina due to de novo disease between January 1, 2018 and November 15, 2019. We defined total cost as the sum of (1) procedural devices-cost, (2) procedural staff-cost, (3) post-percutaneous coronary intervention hospital stay cost, and (4) antiplatelet regime cost. A cost minimization analysis was performed to compare the costs of DCB and DES. Results: We present 1952 all-comer, consecutive patients; 902 (1064 lesions) treated with DCB and 1050 (1236 lesions) treated with DES for de novo coronary artery disease. The cost per patient was estimated to be £9.02 more expensive in the DCB group (£3153.00 vs. £3143.98). However, the cost per lesion treated was calculated to be £15.51 cheaper in the DCB group (£3007.56 vs. £3023.07). The results were consistent irrespective of duration of long-term antiplatelet medications. Conclusion: We have compared the cost-effectiveness of DCB-only angioplasty to DES-angioplasty and showed that the per patient and per lesion results were not different and hence cost should not be implicated in the decision to choose DCB or DES.

Item Type: Article
Additional Information: Funding Information: Vassilios Vassiliou received honoraria for speaking at conferences by Daichii‐Sankyo and Novartis and a research grant from B Braun for investigator‐initiated research. Simon Eccleshall received research grants for investigator‐initiated research and lecture honoraria from B Braun. He also acts as a consultant for B Braun, Medtronic, and MedAlliance. The remaining authors declare no conflict of interest. This is an investigator‐initiated study partially supported by the National Institute for Health Research Capability Fund from Norfolk and Norwich University Hospital and B Braun Ltd. Dr Natasha Corballis was an NIHR Academic Clinical Fellow and is currently funded by the NIHR DRF program.
Uncontrolled Keywords: cost analysis,drug coated balloon,drug eluting stent,radiology nuclear medicine and imaging,cardiology and cardiovascular medicine ,/dk/atira/pure/subjectarea/asjc/2700/2741
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Science > Research Groups > Norwich Epidemiology Centre
Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre
Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 17 Jan 2024 01:37
Last Modified: 18 Jan 2024 01:35
URI: https://ueaeprints.uea.ac.uk/id/eprint/94187
DOI: 10.1002/ccd.30878

Actions (login required)

View Item View Item